Alpine Immune Sciences Inc
NASDAQ:ALPN
Alpine Immune Sciences Inc
NASDAQ:ALPN
Price:
7.7 USD
-1.91%
Market Closed
Updated:
Jun 8, 2024
Alpine Immune Sciences Inc
Capital Expenditures
|
Alpine Immune Sciences Inc
Capital Expenditures Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Alpine Immune Sciences Inc
NASDAQ:ALPN
|
Capital Expenditures
-$416k
|
CAGR 3-Years
19%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Capital Expenditures
-$795m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-4%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Capital Expenditures
-$581m
|
CAGR 3-Years
3%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Capital Expenditures
-$998m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Capital Expenditures
-$464.7m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-41%
|
CAGR 10-Years
-25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Capital Expenditures
-$809.1m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
See Also
What is Alpine Immune Sciences Inc's Capital Expenditures?
Capital Expenditures
-416k
USD
-416k
USD
Based on the financial report for Mar 31, 2024, Alpine Immune Sciences Inc's Capital Expenditures amounts to -416k USD.
What is Alpine Immune Sciences Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
4%
4%
Over the last year, the Capital Expenditures growth was 11%. The average annual Capital Expenditures growth rates for Alpine Immune Sciences Inc have been 19% over the past three years , 4% over the past five years .
You don't have any saved screeners yet
